By the Spotting PTSD team
Spotting PTSD is an evidence-informed toolkit for the prevention and management of Post-Traumatic Stress Disorder in first and emergency responders. The creation of the toolkit first began as a student-initiated master’s project and became a passion and clinical foundation for several team members.
Message posted on behalf of the Faculty of Medicine
Starting Monday February 12th, 2018, the opening hours for the McIntyre Medical Building 3rd floor study space will be extended weekly at night until 20:30 from Monday to Thursday ONLY.
The opening hours are as follows:
- Monday to Thursday from 09:00 to 20:30
- Friday from 09:00 to 17:00
The Faculty of Medicine is pleased to announce the appointment of Dr. Jake Barralet to the position of Director of Innovation for the Steinberg Centre for Simulation and Interactive Learning (SCSIL) and for the Faculty of Medicine at McGill University.
Update - October 5, 2017
This project has been postponed for the time being. More information to come.
The Montreal Neurological Institute and Hospital (The Neuro) is home to Canada’s first multiple sclerosis (MS) clinic, and MS research and treatment has been a major focus at The Neuro for many years. The MS clinic employs a highly specialized staff who have access to the latest research data and methods of treatment. It is a clinic where innovation and progress are paramount.
The ability to remember sounds, and manipulate them in our minds, is incredibly important to our daily lives — without it we would not be able to understand a sentence, or do simple arithmetic. New research is shedding light on how sound memory works in the brain, and is even demonstrating a means to improve it.
Being diagnosed with a malignant brain tumor is devastating news for patients and their loved ones. Whereas some types of tumor respond well to treatment, others such as glioblastomas – the most common and aggressive brain tumors – are known to recur and progress within short times from the diagnosis. Patients diagnosed with this type of cancer, and who undergo current standard treatment, have a median survival of 16 months.
A new mouse model with a working immune system could be used in laboratory research to improve understanding of Zika virus infection and aid development of new treatments, according to a study published in PLOS Pathogens.
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
On Saturday, November 26 from 3am to 5pm, Facilities will be performing renovation work that will affect temperatures in the Schulich Library of Physical Sciences, Life Sciences and Engineering. The steam distribution system in the Macdonald-Stewart Library Building (Schulich Library) will be shut down in order to fix six leaks before the winter season sets in. As a result, library users may experience colder than normal temperatures. Spaces will be open for study but users should dress accordingly.
We apologize for any inconvenience this may cause.
Following the approval of the GD16-09 Renaming Proposal submitted to the Board of Governors on October 6, 2016, Dr. C.
KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.
The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.
Each year, the Department of Obstetrics & Gynecology at McGill organize a symposium to review new studies and practices in order to help practicing gynecologists, family physicians, residents, fellows and allied health professionals with interest in Women’s Health. (Website)
A receptor for the dopamine neurotransmitter promotes growth and spread of pancreatic cancer -- and schizophrenia drugs, which block the function of this receptor, slowed tumor growth and metastatic spread in mice, according to researchers at McGill University and the German Cancer Research Center.
